ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01.11.2022 - ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 31, 2022, the compensation committee of the Company’s Board of Directors approved grants ...